Resources
Sample Assessment: A Robotic Blood-Drawing Device (2020)
By Lloyd Marks · Published
About this sample
I wrote this assessment in April 2020 on the commercial potential of a robotic blood-drawing (phlebotomy) technology developed by a university research group. It is reproduced here as an example of how I approach an assessment. The institution, the device's name, the publications that would identify them and the names of competing products have been removed. Prices, salaries and market figures are as they stood in April 2020 and have not been updated.
The technology
A university research group developed a highly accurate robotic phlebotomy device. Its current version combines ultrasound guidance with three-dimensional near-infrared (NIR) stereoscopy to locate veins, which distinguishes it from the market-leading vein finder, which uses NIR alone. Published studies reported that the device found veins, and succeeded on the first stick, more often than phlebotomists did. A portable handheld version that uses stereoscopic NIR imaging to judge vessel depth also performed well in the laboratory, and a later version was coupled with a point-of-care analyzer, so that blood could be drawn and analyzed within minutes.
The idea of replacing phlebotomists with machines attracted considerable commercial interest. To judge the commercial potential, several issues have to be considered first.
What shapes the market
- Fear of needles. A significant share of patients are needle-phobic, and many of them have fainted on exposure to needles. Vasovagal reactions (a slowing of the heart rate, often with light-headedness) are common, and a small percentage of patients, both experienced and first-time, have a serious reaction with bradycardia and fainting. In my opinion, unattended phlebotomy is therefore unrealistic: someone who can reassure a frightened patient and manage a vasovagal episode must be present however the blood is drawn.
- Machine failures. If a robot is used, someone who can deal with inevitable malfunctions must also be present.
- Labor cost. Phlebotomists earned, on average, about $31,000 a year in 2020, less than physician assistants, and they are trained and experienced in handling frightened patients and vasovagal events.
- Patient acceptance. In informal conversations with eight acquaintances, all said they would be uncomfortable with a robot drawing their blood, especially unattended.
In my opinion, this technology could result in five products, and each should be considered separately on its own merits:
1. an unattended phlebotomy robot 2. an attended phlebotomy robot 3. a handheld device that improves a phlebotomist's first-stick success, without robotic needle insertion and blood withdrawal 4. a handheld device that improves first-stick success, with robotic needle insertion and blood withdrawal 5. a phlebotomy robot coupled with a point-of-care analyzer
Products 1 and 2: phlebotomy robots
Unattended robot. For the reasons above, I believe this is unrealistic and should not be considered a viable product.
Attended robot. Blood-drawing centers typically allow a phlebotomist two attempts before a second phlebotomist tries, and first-stick success is only about 75 percent, so there is room for improvement. The robot could be used for the first stick, or after a failed one. The problem, as I see it, is that unless its use becomes a separately billable procedure, I am not sure hospitals and large commercial laboratories will want to buy it: they almost always get the specimen eventually, even if the patient has to endure several sticks. Patients would still have to be attended, because vasovagal events are unpredictable. Some time might be saved, but phlebotomist salaries are not high. And a device like this would be limited to fixed locations such as blood-drawing facilities, not available at the bedside.
Products 3 and 4: handheld devices
Handheld, without robotic insertion. The market leader in handheld NIR vein finders presents its product as having solved the problem, but its published claims are inconsistent, and while some studies report large improvements in first-stick success, others found none. I remain unconvinced that it helps much. It is, however, financially successful: it was in use in about 2,000 hospitals by 2014, with growth reported at around 40 percent a year.
This is the classic good news and bad news. The bad news is that there are already several competitors. The good news is that there is clearly a large market for handheld devices that improve blood drawing. In my opinion, a superior handheld device that combines stereoscopic NIR with ultrasound would be a successful product; the market leader sold for about $3,900 in 2020, and a superior device at a comparable or higher price would be a formidable competitor. Without the cost of goods and manufacturing, a robust pro forma cannot be produced yet, but this looks like an exciting, viable product. Robotic needle insertion is not essential, as long as the vein-localization technology markedly improves the phlebotomist's first-stick performance, and leaving it out would make the device cheaper, more competitive and portable enough for the bedside.
Handheld, with robotic insertion. If robotic needle insertion and withdrawal improve first-stick performance further, that could be a different, more expensive product. It would be larger, heavier and costlier than the version without insertion, and although it could still be used at the bedside, I am concerned it might be unwieldy.
Testing and market potential of the handheld devices
Testing to settle the form factor. Working prototypes of both handheld versions should be compared head to head with the market leader's latest device, as soon as possible, by opinion leaders in the field. The study would have to show clear superiority over the market leader.
Market potential. There were about 124,000 phlebotomists in the U.S. alone. There were about 924,000 hospital beds; at one unit per 10 beds, that adds about 92,000 potential sales. There were about 9,280 surgery centers; at two units each, that adds about 18,560. That makes potential sales of at least 234,000 units. If, hypothetically, a unit sold for $5,000 and earned $1,000 in profit, that would be about $1.2 billion in potential domestic sales and about $234 million in potential profit.
I like these versions of the product, leaning toward the one without needle insertion because it would be smaller, lighter and less expensive, and I think they should be studied in a clinical trial designed to meet the requirements for FDA approval. That means discussing and designing the trial with the FDA before it is done.
Product 5: a robot coupled with point-of-care testing
Point-of-care testing is a fast-growing market, estimated at about $28 billion in 2019 and growing around 11 percent a year, and a popular analyzer sold for about $6,500. Hospitals and laboratories have embraced it despite its limited test menu and weaker coagulation results compared with standard testing. Combining robotic blood drawing with point-of-care testing is therefore an intriguing idea. The patient would still have to be attended, and it is not yet known whether the results would be better than finger-stick point-of-care testing. I suspect hematology and potassium results would be, because finger sticks cause hemolysis, but whether the combined device would actually improve accuracy is unknown. An inexpensive transfer device already lets blood from a standard tube be moved to a point-of-care analyzer, which could remove the hemolysis errors of a finger stick without a robot; its manufacturer could not tell me whether that also eliminates coagulation-test errors.
Conclusions
1. I am not enthusiastic about the non-handheld versions. Patients must be attended when a robot draws their blood, the device may be intimidating and provoke a vasovagal event, and it is not suitable for bedside use. 2. I am enthusiastic about using some or all of the technology, particularly the ultrasound guidance, to produce a handheld device that competes favorably with the market leader and perhaps makes it obsolete. Adding robotic insertion and withdrawal may or may not improve first-stick success enough to justify a more expensive, heavier and possibly harder-to-use product. I would suggest a rigorous three-arm clinical trial, up to FDA standards, comparing the handheld device without robotic withdrawal, the handheld device with it, and the market leader. The trial should be designed, endorsed and ideally coauthored by a recognized opinion leader in phlebotomy. 3. I am less enthusiastic about the combined robot and point-of-care device. If its results were only as accurate as current finger-stick devices, I see little advantage, and I cannot see it improving throughput much. If they were more accurate, it could improve care, but hospitals and laboratories would still have to buy something that would not necessarily save them money, and some patients will always prefer a finger stick to a needle.
The fastest way to earn money from this invention would be to license the technology to a company that already has access to the target market. A partnership with the current market leader might be worth exploring.
What this sample shows
An assessment separates a technology into the products it could become and tests each one against the people who would use it and the buyers who would pay for it. It is plain about which versions are not viable, estimates the market from stated assumptions, and ends with a concrete next step: here, the clinical trial that would settle the open question, and the route to market most likely to earn a return. For what a current assessment covers, see medical device technology assessment.
Weighing a medical technology?
Tell me briefly what the technology is and what you are deciding. The first consultation is free.
Sources
- Robotic Phlebotomy Critique by Lloyd Marks, April 27, 2020 (the original, unredacted document) — Rebuilt from the text of the legacy file docs/sources/legacy/assets/Example-of-one-of-my-Medical-Invention-Commer.pdf. Not linked: its redaction was only visual.